Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India.
Graphic Era Hill University, Dehradun 248002, India; School of Allied Medical Sciences, Lovely Professional University, Phagwara, Punjab, India.
Int J Pharm. 2024 Jul 20;660:124301. doi: 10.1016/j.ijpharm.2024.124301. Epub 2024 Jun 6.
The application of gold nanoparticles (AuNPs) in cancer therapy, particularly targeted therapy of glioblastoma multiforme (GBM), is an up-and-coming field of research that has gained much interest in recent years. GBM is a life-threatening malignant tumour of the brain that currently has a 95 % death rate with an average of 15 months of survival. AuNPs have proven to have wide clinical implications and compelling therapeutic potential in many researches, specifically in GBM treatment. It was found that the reason why AuNPs were highly desired for GBM treatment was due to their unique properties that diversified the applications of AuNPs further to include imaging, diagnosis, and photothermal therapy. These properties include easy synthesis, biocompatibility, and surface functionalization. Various studies also underscored the ability of AuNPs to cross the blood-brain-barrier and selectively target tumour cells while displaying no major safety concerns which resulted in better therapy results. We attempt to bring together some of these studies in this review and provide a comprehensive overview of safety evaluations and current and potential applications of AuNPs in GBM therapy that may result in AuNP-mediated therapy to be the new gold standard for GBM treatment.
金纳米粒子(AuNPs)在癌症治疗中的应用,特别是多形性胶质母细胞瘤(GBM)的靶向治疗,是近年来备受关注的新兴研究领域。GBM 是一种致命的脑恶性肿瘤,目前的死亡率为 95%,平均存活期为 15 个月。AuNPs 在许多研究中已被证明具有广泛的临床意义和强大的治疗潜力,特别是在 GBM 治疗中。研究发现,AuNPs 之所以非常适合 GBM 治疗,是因为其独特的性质,进一步拓展了 AuNPs 的应用范围,包括成像、诊断和光热治疗。这些性质包括易于合成、生物相容性和表面功能化。各种研究还强调了 AuNPs 穿过血脑屏障和选择性靶向肿瘤细胞的能力,同时没有显示出重大的安全问题,从而导致更好的治疗效果。我们试图在这篇综述中汇集其中一些研究,并提供 AuNPs 在 GBM 治疗中的安全性评估以及当前和潜在应用的全面概述,这可能导致 AuNP 介导的治疗成为 GBM 治疗的新标准。
J Nanobiotechnology. 2022-1-4
Adv Drug Deliv Rev. 2018-11-7
Int J Nanomedicine. 2020-4-23
Curr Med Chem. 2019
Mol Cancer. 2025-3-20
MedComm (2020). 2024-10-20